David is a General Partner at Longwood Fund. Previously, David was co-founder and Chief Innovation Officer at PureTech Health, (LSE: PRTC), where he focused on biotech venture creation and investing. David has served as founding CEO of multiple biotech companies, including Vor Biopharma (NASDAQ:VOR), Pyxis Oncology, Be Biopharma, Vedanta Biosciences, Endra Life Sciences Inc. (NASDAQ: NDRA), and Entrega Biosciences, and co-founded ResTORbio (NASDAQ: TORC). Prior to that David worked in biopharma strategy consulting at Boston Consulting Group and Vertex Partners, and in R&D at P&G Pharmaceuticals. He received his M.B.A. from the University of Chicago Booth School of Business and holds a B.A. in biology from Cornell University.
